Novavax (NVAX) Long-Term Deferred Tax (2018 - 2019)
Novavax (NVAX) recorded quarterly Long-Term Deferred Tax of $2.5 million in Q4 2019, down 20.96% quarter-over-quarter from $3.2 million in Q4 2018, and down 20.96% on a YoY basis from $3.2 million in Q4 2018.
Novavax (NVAX) Long-Term Deferred Tax (2018 - 2019) Analysis & Trends
Novavax's Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $2.5 million for Q4 2019.
- In Q4 2019, Long-Term Deferred Tax fell 20.96% year-over-year to $2.5 million; the TTM figure through Dec 2019 stood at $2.5 million (down 20.96% YoY), while the FY2019 annual figure was $2.5 million, down 20.96% from the prior year.
- Long-Term Deferred Tax was $2.5 million for Q4 2019 at Novavax, down from $3.2 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $3.2 million in Q4 2018 to a low of $2.5 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Novavax | 1.49 Bn | 931.98 Mn | 108.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 2.51 Mn |
| Dec 31, 2018 | 3.18 Mn |